
    
      The objectives of the study are to evaluate the safety, tolerability, and efficacy of 3 doses
      of AVP-923 (dextromethorphan [DM]/quinidine [Q])capsules containing either 45 mg DM and 10 mg
      Q (AVP-923-45) or 30 mg DM 10 mg Q (AVP-923-30) or 20 mg DM and 10 mg Q (AVP-923-20) compared
      to placebo, for the treatment of central neuropathic pain in a population of patients with
      multiple sclerosis (MS) over a 12-week period. The MS patients population enrolled includes
      patients with relapsing-remitting multiple sclerosis (RRMS) and patients with secondary
      progressive multiple sclerosis (SPMS).
    
  